Glucocorticoid receptor is involved in the neuroprotective effect of ginsenoside Rg1 against inflammation-induced dopaminergic neuronal degeneration in substantia nigra

Journal of Steroid Biochemistry and Molecular Biology

Volumn 155, Issue , 2016, Pages 94-103

  Sun, Xian Chang ^a,c   Ren, Xiao Fan ^a,b   Chen, Lei ^a,b   Gao, Xian Qi ^a,b   Xie, Jun Xia ^a,b   Chen, Wen Fang ^a,b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Dopaminergic neuron; Ginsenoside Rg1; Glucocorticoid receptor; LPS; Neuroinflammation; Parkinson's disease

Indexed keywords

DOPAMINE; GINSENOSIDE RG 1; GLUCOCORTICOID RECEPTOR; I KAPPA B; INTERLEUKIN 1BETA; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; APOMORPHINE; GINSENOSIDE; LIPOPOLYSACCHARIDE; NEUROPROTECTIVE AGENT; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME PHOSPHORYLATION; FEMALE; INFLAMMATION; MICROGLIA; NERVE CELL; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; APOMORPHINE; DOPAMINE; FEMALE; GINSENOSIDES; INFLAMMATION; LIPOPOLYSACCHARIDES; MICROGLIA; MIFEPRISTONE; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84944810279     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2015.09.040     Document Type: Article

References (50)

1. P.S. Whitton Inflammation as a causative factor in the aetiology of Parkinson's disease Br. J. Pharmacol. 150 8 2007 963 976
2. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 4 2009 382 397
3. E.C. Hirsch, S. Hunot, P. Damier, and B. Faucheux Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. 44 3 Suppl. 1 1998 S115 S120
4. I. Kurkowska-Jastrzebska, A. Wronska, M. Kohutnicka, A. Czlonkowski, and A. Czlonkowska The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse Exp. Neurol. 156 1 1999 50 61
5. K. Matsuura, H. Makino, and N. Ogawa Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine Exp. Neurol. 146 2 1997 526 535
6. B. Liu, H.M. Gao, and J.S. Hong Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation Environ. Health Perspect. 111 8 2003 1065 1073
7. P.L. McGeer, and E.G. McGeer Glial reactions in Parkinson's disease Mov. Disord. 23 4 2008 474 483
8. Y.Q. Cui, Y.J. Jia, T. Zhang, Q.B. Zhang, and X.M. Wang Fucoidan protects against lipopolysaccharide-induced rat neuronal damage and inhibits the production of proinflammatory mediators in primary microglia CNS Neurosci. Ther. 18 10 2012 827 833
9. C.X. Liu, and P.G. Xiao Recent advances on ginseng research in China J. Ethnopharmacol. 36 1 1992 27 38
10. K. Radad, G. Gille, L. Liu, and W.-D. Rausch Use of ginseng in medicine with emphasis on neurodegenerative disorders J. Pharmacol. Sci. 100 3 2006 175 186
11. K.W. Leung, K.K. Yung, N.K. Mak, Y.S. Chan, T.P. Fan, and R.N. Wong Neuroprotective effects of ginsenoside-Rg1 in primary nigral neurons against rotenone toxicity Neuropharmacology 52 3 2007 827 835
12. X.C. Chen, Y.C. Zhou, Y. Chen, Y.G. Zhu, F. Fang, and L.M. Chen Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress Acta Pharmacol. Sin. 26 1 2005 56 62
13. A. Rhule, S. Navarro, J.R. Smith, and D.A. Shepherd Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264.7 cells J. Ethnopharmacol. 106 1 2006 121 128
14. C.F. Wu, X.L. Bi, J.Y. Yang, J.Y. Zhan, Y.X. Dong, J.H. Wang, J.M. Wang, R.W. Zhang, and M. Li Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia Int. Immunopharmacol. 7 3 2007 313 320
15. Y. Zong, Q.L. Ai, L.M. Zhong, J.N. Dai, P. Yang, Y. He, J. Sun, E.A. Ling, and D. Lu Ginsenoside Rg1 attenuates lipopolysaccharide-induced inflammatory responses via the phospholipase C-gamma 1 signaling pathway in murine BV-2 microglial cells Curr. Med. Chem. 19 5 2012 770 779
16. J.F. Hu, X.Y. Song, S.F. Chu, J. Chen, H.J. Ji, X.Y. Chen, Y.H. Yuan, N. Han, J.T. Zhang, and N.H. Chen Inhibitory effect of ginsenoside Rg1 on lipopolysaccharide-induced microglial activation in mice Brain Res. 1374 2011 8 14
17. M.C. Morale, P.A. Serra, M.R. Delogu, R. Migheli, G. Rocchitta, C. Tirolo, S. Caniglia, N. Testa, F. L'Episcopo, F. Gennuso, G.M. Scoto, N. Barden, E. Miele, M.S. Desole, and B. Marchetti Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide FASEB J. 2003 164 166
18. F. Ros-Bernal, S. Hunot, M.T. Herrero, S. Parnadeau, J.C. Corvol, L. Lu, D. Alvarez-Fischer, M.A. Carrillo-de Sauvage, F. Saurini, C. Coussieu, K. Kinugawa, A. Prigent, G. Hoglinger, M. Hamon, F. Tronche, E.C. Hirsch, and S. Vyas Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism Proc. Natl. Acad. Sci. U. S. A. 108 16 2011 6632 6637
19. Y.J. Lee, E. Chung, K.Y. Lee, Y.H. Lee, B. Huh, and S.K. Lee Ginsenoside-Rg1, one of the major active molecules from Panax ginseng, is a functional ligand of glucocorticoid receptor Mol. Cell. Endocrinol. 133 2 1997 135 140
20. Y. Gao, S. Chu, J. Li, J. Li, Z. Zhang, C. Xia, Y. Heng, M. Zhang, J. Hu, G. Wei, Y. Li, and N. Chen Anti-inflammatory function of Ginsenoside Rg1 on alcoholic hepatitis through glucocorticoid receptor related nuclear factor-kappa B pathway J. Ethnopharmacol. 2015
21. J. Wu, Z. Pan, Z. Wang, W. Zhu, Y. Shen, R. Cui, J. Lin, H. Yu, Q. Wang, J. Qian, Y. Yu, D. Zhu, and Y. Lou Ginsenoside Rg1 protection against β-amyloid peptide-induced neuronal apoptosis via estrogen receptor α and glucocorticoid receptor-dependent anti-protein nitration pathway Neuropharmacology 63 3 2012 349 361
22. L. Xu, W.F. Chen, and M.S. Wong Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway Br. J. Pharmacol. 158 3 2009 738 748
23. Q.-G. Gao, W.-F. Chen, J.-X. Xie, and M.-S. Wong Ginsenoside Rg1 protects against 6-OHDA-induced neurotoxicity in neuroblastoma SK-N-SH cells via IGF-I receptor and estrogen receptor pathways J. Neurochem. 109 5 2009 1338 1347
24. D.K. Khajuria, R. Razdan, and D.R. Mahapatra Description of a new method of ovariectomy in female rats Rev. Bras. Reumatol. 52 3 2012 462 470
25. A.J. Herrera, A. Castano, J.L. Venero, J. Cano, and A. Machado The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system Neurobiol. Dis. 7 4 2000 429 447
26. S.E. Claessens, J.K. Belanoff, S. Kanatsou, P.J. Lucassen, D.L. Champagne, and E.R. de Kloet Acute effects of neonatal dexamethasone treatment on proliferation and astrocyte immunoreactivity in hippocampus and corpus callosum: towards a rescue strategy Brain Res. 1482 2012 1 12
27. S.A. Van Acker, M.F. Fluttert, R.M. Sibug, and E.R. De Kloet Intracerebroventricular administration of a glucocorticoid receptor antagonist enhances the cardiovascular responses to brief restraint stress Eur. J. Pharmacol. 430 1 2001 87 91
28. L.X. Liu, W.F. Chen, J.X. Xie, and M.S. Wong Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease Neurosci. Res. 60 2 2008 156 161
29. H.L. Yuan, B. Li, J. Xu, Y. Wang, Y. He, Y. Zheng, and X.M. Wang Tenuigenin protects dopaminergic neurons from inflammation-mediated damage induced by the lipopolysaccharide CNS Neurosci. Ther. 18 7 2012 584 590
30. J.J. Toledo-Aral, S. Mendez-Ferrer, R. Pardal, and J. Lopez-Barneo Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson's disease Brain Res. Bull. 57 6 2002 847 853
31. D.B. Hoban, E. Connaughton, C. Connaughton, G. Hogan, C. Thornton, P. Mulcahy, T.C. Moloney, and E. Dowd Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat Brain Behav. Immun. 27 1 2013 91 100
32. R. Ladeby, M. Wirenfeldt, D. Garcia-Ovejero, C. Fenger, L. Dissing-Olesen, I. Dalmau, and B. Finsen Microglial cell population dynamics in the injured adult central nervous system Brain Res. Brain Res. Rev. 48 2 2005 196 206
33. E.S. Chung, E. Bok, Y.C. Chung, H.H. Baik, and B.K. Jin Cannabinoids prevent lipopolysaccharide-induced neurodegeneration in the rat substantia nigra in vivo through inhibition of microglial activation and NADPH oxidase Brain Res. 1451 2012 110 116
34. M. Liu, G.Y. Bing, Lipopolysaccharide Animal Models for Parkinson's Disease, Parkinsons Dis-Us (2011).
35. S. Vyas, and L. Maatouk Contribution of glucocorticoids and glucocorticoid receptors to the regulation of neurodegenerative processes CNS Neurol. Disord. Drug Targets 12 8 2013 1175 1193
36. K.L. Ge, W.F. Chen, J.X. Xie, and M.S. Wong Ginsenoside Rg1 protects against 6-OHDA-induced toxicity in MES23. 5 cells via Akt and ERK signaling pathways J. Ethnopharmacol. 127 1 2010 118 123
37. F. Ros-Bernal, S. Hunot, M.T. Herrero, S. Parnadeau, J.C. Corvol, L.X. Lu, D. Alvarez-Fischer, M.A. Carrillo-de Sauvage, F. Saurini, C. Coussieu, K. Kinugawa, A. Prigent, G. Hoglinger, M. Hamon, F. Tronche, E.C. Hirsch, and S. Vyas Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism Proc. Natl. Acad. Sci. U. S. A. 108 16 2011 6632 6637
38. M.A.D. Sauvage, L. Maatouk, I. Arnoux, M. Pasco, A.S. Diez, M. Delahaye, M.T. Herrero, T.A. Newman, C.F. Calvo, E. Audinat, F. Tronche, and S. Vyas Potent and multiple regulatory actions of microglial glucocorticoid receptors during CNS inflammation Cell Death Differ. 20 11 2013 1546 1557
39. I. Kurkowska-Jastrzebska, T. Litwin, I. Joniec, A. Ciesielska, A. Przybylkowski, A. Czlonkowski, and A. Czlonkowska Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease Int. Immunopharmacol. 4 10-11 2004 1307 1318
40. A. Castano, A.J. Herrera, J. Cano, and A. Machado The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma J. Neurochem. 81 1 2002 150 157
41. S. Nadeau, and S. Rivest Glucocorticoids play a fundamental role in protecting the brain during innate immune response J. Neurosci. 23 13 2003 5536 5544
42. J. Du, B. Cheng, X. Zhu, and C. Ling Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects J. Immunol. 187 2 2011 942 950
43. T. Arimoto, D.-Y. Choi, X. Lu, M. Liu, X.V. Nguyen, N. Zheng, C.A. Stewart, H.-C. Kim, and G. Bing Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra Neurobiol. Aging 28 6 2007 894 906
44. M.K. McCoy, T.N. Martinez, K.A. Ruhn, D.E. Szymkowski, C.G. Smith, B.R. Botterman, K.E. Tansey, and M.G. Tansey Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease J. Neurosci. 26 37 2006 9365 9375
45. J.B. Koprich, C. Reske-Nielsen, P. Mithal, and O. Isacson Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease J. Neuroinflammation 5 2008 8
46. M.A. Calzado, S. Bacher, and M.L. Schmitz NF-kappa B inhibitors for the treatment of inflammatory diseases and cancer Curr. Med. Chem. 14 3 2007 367 376
47. M.C. Hernandez-Romero, S. Arguelles, R.F. Villaran, R.M. de Pablos, M.J. Delgado-Cortes, M. Santiago, A.J. Herrera, J. Cano, and A. Machado Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide J. Neurochem. 105 2 2008 445 459
48. Z. Xie, C.J. Smith, and L.J. Van Eldik Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38 Glia 45 2 2004 170 179
49. J.S. Park, M.S. Woo, S.Y. Kim, W.K. Kim, and H.S. Kim Repression of interferon-gamma-induced inducible nitric oxide synthase (iNOS) gene expression in microglia by sodium butyrate is mediated through specific inhibition of ERK signaling pathways J. Neuroimmunol. 168 1-2 2005 56 64
50. C. Svensson, S.Z. Fernaeus, K. Part, K. Reis, and T. Land LPS-induced iNOS expression in Bv-2 cells is suppressed by an oxidative mechanism acting on the JNK pathway - a potential role for neuroprotection Brain Res. 1322 2010 1 7